Effects of Resveratrol Co-Administration on Celecoxib Disposition and Pharmacokinetics in Healthy Volunteers

Author:

Helal Nagwa I.1,El-Khodary Noha M.2ORCID,Omran Gamal A.3,El-Masry Soha M.4

Affiliation:

1. Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy Damanhour University, Damanhour City, Egypt

2. Department of Clinical Pharmacy, Faculty of Pharmacy Kafrelsheikh University, Kafrelsheikh City, Egypt

3. Department of Biochemistry, Faculty of Pharmacy Damanhour University, Damanhour City, Egypt

4. Department of Pharmaceutics, Faculty of Pharmacy Damanhour University, Damanhour City, Egypt

Abstract

AbstractThe objective of the current study was to investigate the effects of resveratrol (RSV), a natural herbal remedy used as an adjacent anti-inflammatory supplement on, the pharmacokinetics of celecoxib in healthy male volunteers. Twelve healthy human participants were involved in two-period open-labeled trial. Celecoxib (200 mg) was given as a single oral dose under fasting conditions as a control phase. Afterward, RSV (500 mg) commenced as a single oral dose for ten days as a treatment phase. Blood samples were collected during the control and treatment phases and analyzed using the validated High-performance liquid chromatography (HPLC) method. RSV pre-exposure significantly increased the area under the curve (AUC0–24), peak plasma concentration (Cmax), absorption rate constant (ka), and prolongated half-life (t1/2), along with a decrease in elimination rate constant (ke). Meanwhile, the volume of distribution (Vd/F) and apparent total body clearance (CL/F) were significantly decreased for celecoxib. There was no significant change in the time it takes for celecoxib to reach the maximum concentration (tmax) was observed. The obtained results suggested the presence of a beneficial pharmacokinetic interaction between RSV and celecoxib. Consequently, combining resveratrol as an herbal remedy and celecoxib as an anti-inflammatory drug may synergistically reduce inflammation and osteoarthritis with minimal side effects.

Publisher

Georg Thieme Verlag KG

Subject

Drug Discovery,General Medicine

Reference44 articles.

1. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation;Y F Chen;Health Technol Assess,2008

2. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis;H B Fung;Clin Ther,1999

3. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract;C Sostres;Best Pract Res Clin Gastroenterol,2010

4. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs;G García-Rayado;Expert Rev Clin Pharmacol,2018

5. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs;D Thomas;Am J Cardiovasc Drugs,2017

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3